| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 24 Jan 2025 | 16 Jan 2025 |
| TRANSGENE BIOTEK LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 inter alia to consider and approve 1. To consider and approve the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended December 31 2024.Along with (Standalone & Consolidated) Limited review report thereon. 2. To transact such other business as may be required. This has reference to our letter dated January 16 2025. 1) The Board has considered and approved the unaudited Consolidated & Standalone Financial Results of the company, for the Quarter ended 31.12.2024 in accordance with the Indian Accounting Standards (IND-AS) as per Companies (Indian Accounting Standards) Rules, 2015. 2) Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company, for the quarter ended 31.12.2024 has also been approved. 3) The Board has discussed and approved a funding proposal to raise funds on a securitized basis to address the pressing demands on the company and passed appropriate resolution to move the proposal forward. The meeting commenced at 11:00 a.m. and concluded at 12:25 p.m. Financial Results 31-12-2024. (As Per BSE Announcement Dated on 24/01/2025) | ||
| Board Meeting | 12 Nov 2024 | 4 Nov 2024 |
| TRANSGENE BIOTEK LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve 1) To consider and approve the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and half yearly ended on September 30 2024. 2) To consider and approve the Limited Review Report (Standalone & Consolidated) for the quarter and half yearly ended on ended September 30 2024. 3) To consider and approve the Notice of the 34th Annual General Meeting for the financial Year 2023-24 and other related matters thereto. 4) To consider and approve Directors Report and the annexure thereon for the financial year 2023-24. 5) To fix Record Date Book Closure date and E voting dates etc. 6) To Appoint a Scrutinizer for the e voting Process. 7) To transact such other business as may be required. Outcome of Board Meeting. (As Per BSE Announcement Dated on 12.11.2024) Revised Results (As Per BSE Announcement Dated on: 13/11/2024) | ||
| Board Meeting | 10 Aug 2024 | 19 Jul 2024 |
| TRANSGENE BIOTEK LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2024 inter alia to consider and approve In order to transact following businesses. Outcome of the Board Meeting. The Unaudited Financial Results . (As Per BSE Announcement Dated on 10.08.2024) | ||
| Board Meeting | 30 May 2024 | 12 May 2024 |
| TRANSGENE BIOTEK LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve 1) To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended 31st March 2024. 2) Any other Business matter with the permission of the Chair. Outcome of Board Meeting and submission of Audited Financial Results for the financial year ended March 31, 2024 Audited Results (As Per BSE Announcement Dated on 30.05.2024) Revised Outcome of Board Meeting (As Per BSE Announcement Dated on: 28/06/2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
